A combination preparation based on antibiotic, cluster silver and bacteriophage for treatment of infectious diseases caused by Staphylococcus aureus and S. aureus MRSA
- Authors: Pugachev V.G.1, Totmenina O.D.1
-
Affiliations:
- State Research Center of Virology and Biotechnology “Vector”, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing
- Issue: Vol 13, No 2 (2023)
- Pages: 383-390
- Section: SHORT COMMUNICATIONS
- URL: https://bakhtiniada.ru/2220-7619/article/view/147834
- DOI: https://doi.org/10.15789/2220-7619-ACP-3667
- ID: 147834
Cite item
Full Text
Abstract
The problems of bacterial infections in medicine and veterinary medicine require careful study and rapid solution. Due to continuous and, in some cases, irrational use of antibiotics, the efficiency of their effect on host has been noticeably decreasing; moreover, resistance to antibacterial drugs is steadily growing, antibiotic-resistant strains emerge, which are not amenable to conventional medical treatment. The unprecedented rise of pathogenic bacteria resistance to antibiotics requires generation of new drugs to combat them. One of the ways to increase the effectiveness of antibiotic therapy is to use combination drugs. Combination dosage forms provide an increased therapeutic effect and should not be toxic to the body. To overcome the microbial resistance reducing host burden of antibiotics, we proposed a combination preparation based on antibiotic, cluster silver and specific bacteriophage for treatment of infectious diseases caused by S. aureus, including MRSA strains. Each component has already proven in the treatment of pathogen-caused infectious diseases. But while using this combination agent, it became possible to reduce the amount of antibiotic and get rid of antibiotic-resistant and phage-resistant forms of bacteria. The study showed the effectiveness of the combination preparation on S. aureus MRSA bacteria, while reducing the amount of antibiotics in proposed composition by 2–4 times compared to use of antibiotic alone. The efficacy of the preparation containing was as follows: 10 mg/ml gentamicin, 7 mg/ml cluster silver and 106 BOV/ml bacteriophage, on S. aureus MRSA bacteria in suspension is comparable to the effectiveness of gentamicin with a concentration of 40 mg/ml. For S. aureus 209 and S. aureus ssp. bacteria with reduced resistance to antibiotics, the use of two-component compositions (antibiotic + cluster silver; antibiotic + bacteriophage) also allowed to reduce the antibiotic concentration by 2–3 times. It should be noted that with a constant amount of antibiotic, increasing the amount of cluster silver by 4–5 times, there is a rise in bactericidal properties of the resulting preparations. Repeated introduction of drug dose allows to achieve a marked decrease in level of pathogenic microorganisms in the suspension studied. This drug has no limitations depending on the state and degree of microbial resistance.
Full Text
##article.viewOnOriginalSite##About the authors
Vladimir G. Pugachev
State Research Center of Virology and Biotechnology “Vector”, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing
Author for correspondence.
Email: pugachev@vector.nsc.ru
Senior Researcher
Russian Federation, Koltsovo, Novosibirsk RegionOlga D. Totmenina
State Research Center of Virology and Biotechnology “Vector”, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing
Email: pugachev@vector.nsc.ru
Researcher
Russian Federation, Koltsovo, Novosibirsk RegionReferences
- Афонина И.А., Краева Л.А., Ценева Г.Я. Характеристика чувствительности Staphylococcus aureus и Сandida albicans к противомикробным препаратам и коллоидному серебру. // Инфекция и иммунитет. 2011, Т. 1, № 2. С. 177–180. [Afonina I.A., Kraeva L.A., Tseneva G.Y. Characteristic of sensitivity of staphylococcus aureus and candida albicans to antibacterial preparations and colloidal silver. Infektsiya i immunitet = Russian Journal of Infection and Immunity, 2011, vol. 1, no. 2, pp. 177–180. (In Russ.)]
- Асланов Б.И., Зуева Л.П., Кафтырева Л.А., Бойцов А.Г., Акимкин В.Г., Долгий А.А., Брусина Е.Б., Дроздова О.М. Рациональное применение бактериофагов в лечебной и противоэпидемической практике. Федеральные клинические рекомендации. М., 2014. 39 с. [Aslanov B.I., Zueva L.P., Kaftyreva L.A., Boytsov A.G., Akimkin V.G., Dolgiy A.A., Brusina E.B., Drozdova O.M. Rational use of bacteriophages in therapeutic and antiepidemic practice. Federal clinical guidelines. Moscow, 2014. (In Russ.)]
- Божкова С.А., Полякова Е.М., Краснова М.В. Преодоление устойчивости к гентамицину у метициллинорезистентных штаммов стафилококка // Международный журнал прикладных и фундаментальных исследований. 2017. № 8, Ч. 1. С. 97–103. [Bozhkova S.A., Polyakova E.M., Krasnova M.V. The breaking of resistance to gentamycin in methicillin resistant Staphylococcus aureus strains. Mezhdunarodnyi zhurnal prikladnykh i fundamental’nykh issledovanii = International Journal of Applied and Fundamental Research, 2017, no. 8, pt 1, pp. 97–103. (In Russ.)]
- Патент № 2672869 Российская Федерация, МПК A61K 35/76 (2015.01); A61K 33/38 (2006.01); A61K 47/06 (2006.01); A61P 31/04 (2006.01). Антибактериальное средство на основе бактериофага: № 2017142076; заявлено 2017.12.01: опубликовано 2018.11.20. / Пугачев В.Г., Тотменина О.Д. Патентообладатель: ФБУН ГНЦ ВБ «Вектор» Роспотребнадзора. 14 с. [Patent No. 2672869 Russian Federation, Int. Cl. A61K 35/76 (2015.01); A61K 33/38 (2006.01); A61K 47/06 (2006.01); A61P 31/04 (2006.01). Antibacterial agent based on bacteriophage. No. 2017142076; application: 2017.12.01: date of publication 2018.11.20 / Pugachev V.G., Totmenina O.D. Proprietor: Federalnoe byudzhetnoe uchrezhdenie nauki “Gosudarstvennyj nauchnyj tsentr virusologii i biotekhnologii “Vektor” Federalnoj sluzhby po nadzoru v sfere zashchity prav potrebitelej i blagopoluchiya cheloveka (FBUN GNTS VB “Vektor” Rospotrebnadzora). 14 p.]
- Шкиль Н.А., Бурмистров В.А., Соколов М.Ю. Антимикробные свойства, фармакотоксикологические характеристики и терапевтическая эффективность препарата арговит при желудочно-кишечных болезнях телят // Научный журнал КубГАУ. 2011. № 68 (04). 11 c. [Shkil N.A., Burmistrov V.A., Sokolov M.Yu. Antimicrobial properties, pharmacotoxicological characteristics and therapeutic efficacy of argovit in gastrointestinal diseases of calves. Nauchnyi zhurnal KubGAU = KubGAU Scientific Journal, 2011, no. 68 (04), 11 p. (In Russ.)]
- Харсеева Г.Г., Фролова Я.Н., Миронов А.Ю. Биопленки патогенных бактерий: биологические свойства и роль в синхронизации инфекционного процесса // Успехи современной биологии. 2015. Т. 135, № 4. С. 346–354. [Kharseeva G.G., Frolova Ya.N., Mironov A.Yu. Biofilms of pathogenic bacteria: biological properties and their role in chronization of inflammatory process. Uspekhi sovremennoi biologii = The Successes of Modern Biology, 2015, vol. 135, no. 4, pp. 346–354. (In Russ.)]
- Методические указания по определению чувствительности микроорганизмов к антибактериальным препаратам. МУК 4.12.1890-04. М., 2004. 65 с. [Guidelines for determining the sensitivity of microorganisms to antibacterial drugs. MUK 4.12.1890-04. Moscow, 2004. 65 p. (In Russ.)]
- Miroshnikov K.A., Kulikov E.E., Darbeeva O.S., Lysko K.A., Ignat’ev G.M. [Genetic and molecular principles for the selection of Pseudomonas and Staphylococcus therapeutic bacteriophages]. Prikl. Biokhim. Mikrobiol., 2014, vol. 50, no. 3, pp. 338–344. (In Russ.)
- Morones-Ramirez J.R., Winkler J.A., Spina C.S., Collins J.J. Silver enhances antibiotic activity against gram-negative bacteria. Sci. Transl. Med., 2013, vol. 5, no. 190: 190ra81. doi: 10.1126/scitranslmed.3006276
- Ruden S., Hilpert K., Berditsch M., Wadhwani P., Ulrich A.S. Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides. Antimicrob. Agents Chemother., 2009, vol. 53, no. 8, pp. 3538–3540. doi: 10.1128/AAC.01106-08
Supplementary files
